Další formáty:
BibTeX
LaTeX
RIS
@article{1399419,
author = {Berthold, Frank and Hömberg, Marc and Proleskovskaja, Inna and Mazánek, Pavel and Belogurova, Margarita and Ernst, Angela and Štěrba, Jaroslav},
article_location = {Philadelphia},
article_number = {5},
doi = {http://dx.doi.org/10.1080/08880018.2017.1373314},
keywords = {Angiogenesis; dose-intense chemotherapy; immunomodulation; metronomic therapy; neuroblastoma},
language = {eng},
issn = {0888-0018},
journal = {Pediatric Hematology and Oncology},
title = {Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma},
volume = {34},
year = {2017}
}
TY - JOUR
ID - 1399419
AU - Berthold, Frank - Hömberg, Marc - Proleskovskaja, Inna - Mazánek, Pavel - Belogurova, Margarita - Ernst, Angela - Štěrba, Jaroslav
PY - 2017
TI - Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma
JF - Pediatric Hematology and Oncology
VL - 34
IS - 5
SP - 308-319
EP - 308-319
PB - Taylor & Francis
SN - 08880018
KW - Angiogenesis
KW - dose-intense chemotherapy
KW - immunomodulation
KW - metronomic therapy
KW - neuroblastoma
N2 - The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experienced 1-3 recurrences and had 1-3 sites involved (osteomedullary, primary tumor, central nervous system, lymph nodes, liver, lungs) before the metronomic therapy started. Two patients in complete remission and three with active refractory disease following recurrence treatment were excluded from the outcome analysis. The curves for secondary event-free and overall survival demonstrated no significant differences.
ER -
BERTHOLD, Frank, Marc HÖMBERG, Inna PROLESKOVSKAJA, Pavel MAZÁNEK, Margarita BELOGUROVA, Angela ERNST a Jaroslav ŠTĚRBA. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. \textit{Pediatric Hematology and Oncology}. Philadelphia: Taylor \&{} Francis, 2017, roč.~34, č.~5, s.~308-319. ISSN~0888-0018. Dostupné z: https://dx.doi.org/10.1080/08880018.2017.1373314.
|
